Latest News

Dec 13, 2007

Health Enhancement Products signs contract with Specialty Nutrition Group, Inc for Re-Branding and Product Marketing of ProAlgaZyme.


Nov 14, 2007

Health Enhancement Products Announced the Long Awaited Discovery of a Class of "Orally Active Agents" in Its Primary Product, ProAlgaZyme


Nov 6, 2007

Health Enhancement Products Reports Results in the Second Testing of the ProAlgaZyme Clinical Lot Used in the Suspended Clinical Trial


Oct 25, 2007

Health Enhancement Products Reports Results in Testing of the ProAlgaZyme Clinical Lot Used in the Suspended Clinical Trial



Health Enhancement Products is a member of these organizations







 
Health Enhancement Products Files for Patent Covering ProAlgaZyme Product

April 29 2004, 08:30am ET


TEMPE, Ariz., April 29/PRNewswire-FirstCall/ - Health Enhancement Products, Inc. today announced that it has filed a patent application with the U.S. Patent and Trademark Office, relating generally to a method of preparation of a phyto-percolate. This patent filing will also protect the use of phyto-percolate in the treatment of a variety of diseases including cancer, cardiovascular disease, and diseases related to immune system deficient disorders. The phyto-percolate is a proteolytic enzyme complex derived from a specific combination of fresh water algae that expresses plasmin-like activity. As humans' age and chronic disease processes progress, a deficiency of the proteolytic enzymes that carry out the body's waste detoxification processes may be experienced. A deficiency of this enzyme can cause a chronic hyper-inflammatory state, and the disease process becomes much more complex. Without adequate enzymes in the body, the immune system and other metabolic processes become less efficient, making tissue repair slow and poorly replicated.

The patent application is for a method of treating or preventing a disease or disorder in a human by ingesting a phyto-percolate derived from mixtures including freshwater algae, in this case being ProAglaZyme. There are several aspects of this patent application, including methods of treating immune system deficiency, type I and II diabetes, diseases related to the heart, Cancer, Arthritis, and most other diseases related to a deficient immune system.

Howard Baer, Chief Executive Officer of Health Enhancement Products, Inc., said, "Based on the preliminary results we have had with our various studies involving ProAlgaZyme, filing for this patent was a logical step. We have several different initiatives underway and want to be able to legally protect our interests appropriately."




About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (OTC: HEPI) is a nutraceutical company directed specifically at the development and marketing of supplementary health-enhancing products using only pure, all-natural and herbal extracts. In particular, Health Enhancement's products use beneficial herbal extracts, vitamins, minerals, and botanical extracts in varying combinations to address common or specific illnesses.

The Company's sole product is ProAlgaZyme that is produced from an algae grown in 100% distilled water. The algae produces an enzyme as a means of protecting itself from exposure to outside disease and harmful bacteria. The enzyme is then drawn off, filtered, tested and bottled for consumption. Recent clinical trials performed by the Company have indicated that ProAlgaZyme may increase and activate the white blood cells in individuals whose white cells are low or inactive, in effect enhancing the immune system. Heath Enhancements is currently doing internal clinical trials on several illnesses and diseases with ProAlgaZyme, including various types of cancer, HIV/AIDS, diabetes and Chronic Fatigue Syndrome.

ReplenTish is currently available for sale exclusively on
our websites www.heponline.com or www.replentish.com .


CONTACTS:
Health Enhancement Products, Inc.
480-385-3800

This press release may contain forward-looking statements. The words "estimate," "possible" and "seeking" and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.


© 2007 HEALTH ENHANCEMENT PRODUCTS INC.
            PRIVACY POLICY           DISCLAIMER 

 

v5Design.Com